Craig Hallum Raises Indivior (NASDAQ:INDV) Price Target to $22.00

Indivior (NASDAQ:INDV - Free Report) had its target price hoisted by Craig Hallum from $15.00 to $22.00 in a research note published on Monday morning,Benzinga reports. The firm currently has a buy rating on the stock.

INDV has been the topic of a number of other reports. Wall Street Zen raised Indivior from a "buy" rating to a "strong-buy" rating in a research note on Saturday, June 21st. Piper Sandler dropped their target price on Indivior from $16.00 to $13.00 and set an "overweight" rating for the company in a report on Thursday, March 6th. Three investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $17.00.

Indivior Stock Performance

Shares of NASDAQ INDV traded up $0.69 during trading hours on Monday, reaching $16.09. 2,981,689 shares of the stock traded hands, compared to its average volume of 1,234,663. The company's 50-day simple moving average is $12.60 and its two-hundred day simple moving average is $11.21. Indivior has a 52-week low of $7.33 and a 52-week high of $16.09.

Indivior (NASDAQ:INDV - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The company reported $0.41 earnings per share for the quarter, topping analysts' consensus estimates of $0.22 by $0.19. Indivior had a negative net margin of 4.02% and a negative return on equity of 97.29%. The firm had revenue of $266.00 million during the quarter, compared to analyst estimates of $240.13 million. On average, sell-side analysts anticipate that Indivior will post 1.22 EPS for the current fiscal year.

Hedge Funds Weigh In On Indivior

Several hedge funds and other institutional investors have recently modified their holdings of INDV. Deerfield Management Company L.P. Series C increased its holdings in Indivior by 74.4% during the 4th quarter. Deerfield Management Company L.P. Series C now owns 8,883,160 shares of the company's stock valued at $110,418,000 after purchasing an additional 3,790,518 shares during the period. Goldman Sachs Group Inc. boosted its holdings in Indivior by 18.4% in the first quarter. Goldman Sachs Group Inc. now owns 8,368,996 shares of the company's stock valued at $79,757,000 after acquiring an additional 1,299,425 shares in the last quarter. Jane Street Group LLC increased its position in Indivior by 2,597.9% during the 1st quarter. Jane Street Group LLC now owns 995,013 shares of the company's stock valued at $9,327,000 after purchasing an additional 958,132 shares during the period. Claret Asset Management Corp purchased a new stake in shares of Indivior in the 4th quarter worth about $9,304,000. Finally, Acadian Asset Management LLC purchased a new stake in shares of Indivior in the 1st quarter worth about $6,328,000. 60.33% of the stock is owned by institutional investors.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.